KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

The efficacy and safety of Anyu Peibo Capsule in the treatment of patients with major depressive disorder in China: study protocol for a randomized placebo-controlled trial.

Jingjing Huang, Yimin Yu, Yi Jiang, Wu Chen, Yan Li, Yifeng Shen, Qingshan Zheng, Huafang Li

Trials 22(1) 585

PMID34479619
PMCIDPMC8414707
DOI10.1186/s13063-021-05550-9
发表日期2021-09-04
摘要

摘要

BACKGROUND: Major depressive disorder is the second leading cause of years lost to disability worldwide. Anyu Peibo Capsule has been shown to be effective and safe in phase II trials. METHODS: This clinical study is a multi-center, randomized, double-blinded, placebo-controlled, parallel-group, phase III trial of Anyu Peibo Capsule in China. The aim is to test whether the administration of Anyu Peibo Capsule compared to placebo improves clinical outcomes in adults (aged 18 to 65 years) with MDD. Patients will receive an 8-week treatment of Anyu Peibo Capsule 1.6 g per day or placebo. The primary outcome will be the change from baseline in the total score for the Montgomery-Asberg Depression Rating Scale at the end of the 8-week treatment. DISCUSSION: The trial aims to provide pivotal evidence for the efficacy and safety of Anyu Peibo Capsule in patients with major depressive disorder. TRIAL REGISTRATION: ClinicalTrials.gov NCT04210973 . Registered on December 26, 2019.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。